Accord Healthcare

Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to more than 70 countries globally.
 

ADVERSE DRUG
REACTION
REPORT

GROWTH’S IN OUR NATURE

Accord Healthcare is one of the fastest growing generic pharmaceutical companies in the UK & Ireland.

Acquiring Actavis UK and Ireland in 2017 facilitates Accord’s ambition to become a top 5 pan-EMENA generics company by 2021 and have developed a specialty products commercialisation capability.

01

TRULY MULTINATIONAL

Accord has one of the most extensive sales, marketing and distribution networks in Europe. Headquartered from UK, Accord now supplies products to close to 65 EMENA markets.

02

A COMPLETE APPROACH

Accord’s vision is to be involved in all aspects of bringing pharmaceuticals to patients. Our activities today encompass the entire pharmaceutical value chain and so create a truly integrated offering.

03

EUROPEAN FOCUS

Accord currently has a portfolio comprising nearly 7000 product approvals in Europe. We operate a pan European commercial footprint with direct presence in all major EU markets.

04

News

19-10-2018

Accord acts differently to plot a path towards further growth

James Burt, EVP EMENA and Paul Tredwell, VP Specialty Brands met with Aidan Fry from Generics Bulletin to talk about Accord’s continued rise across Europe in hospital and retail generics and their exciting new developments in added-value products, including biosimilars.

10-10-2018

Accord Healthcare - the most recognised company at the Global Generics & Biosimilar Awards 2018

We are delighted to announce that Accord Healthcare was the most recognised company at the Global Generics & Biosimilar Awards 2018, having won awards for: Company of the Year and Biosimilar Initiative of the Year.  As well, Intas & Accord Healthcare also picked up the award for Company of the Year Asia-Pacific.